탁원영 프로필 사진

탁원영

Tak Wonyoung

의과대학

의학과

Web Of Science Scopus ORCID

자료 필터

자료유형

발행연도

2022 ~ 2025
2022 2025

키워드

언어

전체 61건 중 11번부터 20번까지의 결과를 표시합니다.

2025
Article

Inter-Slice Dual Cross Attention and Class-Level Alignment for 2.5D Medical Image Segmentation

  • 2025
  • 2025 IEEE INTERNATIONAL CONFERENCE ON ADVANCED VISUAL AND SIGNAL-BASED SYSTEMS, AVSS
  • IEEE
2024
Article

Phase Ib/IIa randomized study of heterologous ChAdOx1HBV/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB

  • Tak, Won Young ; 
  • Chuang, Wan-Lobg ; 
  • Chen, Chi-Yi ; 
  • Tseng, Kuo-Chih ; 
  • Lim, Young-Suk ; 
  • 외 14명
  • 2024-12
  • Journal of Hepatology
  • ELSEVIER
Article

VIR-2218 (elebsiran) plus pegylated interferon-alfa-2a in participants with chronic hepatitis B virus infection: a phase 2 study

  • Yuen, Man-Fung ; 
  • Lim, Young-Suk ; 
  • Yoon, Ki Tae ; 
  • Lim, Tien-Huey ; 
  • Heo, Jeong ; 
  • ... Tak, Won Young ; 
  • 외 9명
  • 2024-12
  • LANCET GASTROENTEROLOGY & HEPATOLOGY
  • ELSEVIER INC
Article

Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification

  • 2024-10-02
  • Scientific Reports
  • NATURE PORTFOLIO
Article

mRECIST Outcomes in EMERALD-1: A Phase 3, Randomized, Placebo-Controlled Study of Transarterial Chemoembolization plus Durvalumab with or without Bevacizumab in Participants with Embolization-Eligible Hepatocellular Carcinoma

  • Sangro, B. ; 
  • Kudo, M. ; 
  • Erinjeri, J. P. ; 
  • Qin, S. ; 
  • Ren, Z. ; 
  • ... Tak, W. Y. ; 
  • 외 14명
  • 2024-10-01
  • International Journal of Radiation Oncology Biology Physics
  • ELSEVIER SCIENCE INC
Article

BENEFICIAL EFFECT OF COMBINED RADIATION THERAPY IN ATEZOLIZUMAB PLUS BEVACIZUMAB TREATMENT OF HEPATOCELLULAR CARCINOMA PATIENTS WITH MAIN PORTAL VEIN TUMOR THROMBOSIS OR BILE DUCT INVASION

  • 2024-10
  • Hepatology
  • LIPPINCOTT WILLIAMS & WILKINS
Article

CIRCULATING EXOPD-L1 PREDICTS THE OUTCOME OF PATIENTS WITH HCC WHO RECEIVED ATEZOLIZUMAB-BEVACIZUMAB

  • 2024-10
  • Hepatology
  • LIPPINCOTT WILLIAMS & WILKINS